What is Tildrakizumab: Uses, Dosage, Side Effects and More

Tildrakizumab is a prescription medication that helps treat moderate to severe plaque psoriasis in adults. This injectable medicine works by targeting specific proteins in your immune system that contribute to psoriasis symptoms.

If you're dealing with psoriasis patches that cover a significant portion of your body or haven't responded well to other treatments, your doctor might recommend tildrakizumab as part of your treatment plan. It's designed to help clear your skin and reduce the inflammation that causes those uncomfortable, scaly patches.

What is Tildrakizumab?

Tildrakizumab is a type of medication called a monoclonal antibody that specifically targets psoriasis. It belongs to a class of drugs known as biologics, which are made from living cells rather than chemicals.

This medication comes as a prefilled syringe or pen that you inject under your skin (subcutaneously). The brand name for tildrakizumab is Ilumya, and it's specifically approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Unlike topical creams or pills, tildrakizumab works from within your body to address the root cause of psoriasis inflammation. It's considered a targeted therapy because it focuses on specific immune system pathways involved in psoriasis development.

What is Tildrakizumab Used For?

Tildrakizumab is primarily used to treat moderate to severe plaque psoriasis in adults. This means it's prescribed when your psoriasis covers a significant area of your body or significantly impacts your quality of life.

Your doctor might recommend tildrakizumab if you have psoriasis that hasn't responded well to topical treatments like creams and ointments. It's also an option if you're a candidate for systemic therapy, which means treatments that work throughout your entire body rather than just on the skin's surface.

The medication is specifically designed for plaque psoriasis, which is the most common form of psoriasis. This type causes raised, red patches covered with silvery scales that can appear anywhere on your body but commonly affect your elbows, knees, scalp, and lower back.

How Does Tildrakizumab Work?

Tildrakizumab works by blocking a specific protein called interleukin-23 (IL-23) in your immune system. This protein plays a key role in triggering the inflammation and rapid skin cell growth that characterizes psoriasis.

Think of IL-23 as a messenger that tells your immune system to create inflammation in your skin. By blocking this messenger, tildrakizumab helps reduce the overactive immune response that leads to psoriasis symptoms.

This medication is considered moderately strong among psoriasis treatments. It's more targeted than some older systemic medications, which means it has fewer effects on your overall immune system while still being effective for psoriasis symptoms.

The blocking action helps slow down the rapid skin cell turnover that creates those thick, scaly patches. Over time, this can lead to clearer skin and reduced inflammation in the affected areas.

How Should I Take Tildrakizumab?

Tildrakizumab is given as an injection under your skin, typically in your thigh, stomach area, or upper arm. Your healthcare provider will teach you how to inject it yourself, or you can have it done at a medical office.

The medication comes in a prefilled syringe or pen device that makes self-injection easier. You'll need to let the medication reach room temperature before injecting, which usually takes about 30 minutes after removing it from the refrigerator.

You can take tildrakizumab with or without food since it's injected rather than taken by mouth. However, you should rotate injection sites to prevent skin irritation and avoid injecting into areas where your skin is tender, bruised, or affected by psoriasis.

Before each injection, clean your hands thoroughly and clean the injection site with an alcohol swab. Make sure to dispose of used needles and syringes safely in a sharps container.

How Long Should I Take Tildrakizumab For?

Most people start with an initial dose, followed by another dose 4 weeks later, then continue with doses every 12 weeks. Your doctor will determine the exact schedule that's right for your specific situation.

Psoriasis is a chronic condition, which means tildrakizumab is typically a long-term treatment. Many people continue taking it for months or years to maintain clear skin and prevent psoriasis symptoms from returning.

You might start noticing improvements in your skin within the first few weeks, but it can take up to 12-16 weeks to see the full effects. Your doctor will monitor your progress and may adjust your treatment plan based on how well you respond.

Never stop taking tildrakizumab suddenly without talking to your doctor first. Stopping abruptly could cause your psoriasis symptoms to return or worsen.

What Are the Side Effects of Tildrakizumab?

Like all medications, tildrakizumab can cause side effects, though not everyone experiences them. Most side effects are mild to moderate and manageable with proper monitoring.

Here are the most common side effects you might experience:

• Upper respiratory tract infections like colds or sinus infections
• Injection site reactions such as redness, swelling, or mild pain
• Diarrhea or stomach discomfort
• Back pain or muscle aches
• Headaches

These common side effects usually improve as your body adjusts to the medication, and most people can continue their treatment without interruption.

Some less common but more serious side effects require immediate medical attention:

• Signs of serious infection like fever, chills, or persistent cough
• Unusual fatigue or weakness
• Severe allergic reactions with difficulty breathing or swelling
• New or worsening inflammatory bowel disease symptoms
• Skin reactions beyond the injection site

Rare but serious side effects can include increased risk of certain infections or potential effects on your liver function. Your doctor will monitor you regularly with blood tests to catch any issues early.

Who Should Not Take Tildrakizumab?

Tildrakizumab isn't right for everyone, and certain health conditions or situations make it unsuitable or require special precautions.

You should not take tildrakizumab if you have an active serious infection anywhere in your body. This includes bacterial, viral, fungal, or parasitic infections that haven't been treated and resolved.

People with certain medical conditions need careful evaluation before starting tildrakizumab:

• History of recurring infections or conditions that increase infection risk
• Inflammatory bowel disease like Crohn's disease or ulcerative colitis
• Recent vaccinations with live vaccines
• Tuberculosis or exposure to tuberculosis
• Hepatitis B or C infections

Your doctor will need to assess these conditions carefully because tildrakizumab affects your immune system and could potentially worsen certain health problems.

Pregnancy and breastfeeding require special consideration. While there's limited data on tildrakizumab's safety during pregnancy, you should discuss the risks and benefits with your doctor if you're pregnant, planning to become pregnant, or breastfeeding.

Tildrakizumab Brand Name

The brand name for tildrakizumab is Ilumya. This is the name you'll see on your prescription bottle and medication packaging.

Ilumya is manufactured by Sun Pharmaceutical Industries and was approved by the FDA in 2018 for treating moderate to severe plaque psoriasis in adults. It's the only brand name version of tildrakizumab currently available.

When talking to your doctor or pharmacist, you can refer to your medication as either tildrakizumab or Ilumya - they're the same medication. Your insurance coverage and pharmacy might use either name when processing your prescription.

Tildrakizumab Alternatives

Several other biologic medications work similarly to tildrakizumab for treating psoriasis. These alternatives target different proteins in the immune system but aim to achieve similar results.

Other IL-23 inhibitors like tildrakizumab include guselkumab (Tremfya) and risankizumab (Skyrizi). These medications work through the same pathway and have similar effectiveness and side effect profiles.

Additional biologic alternatives target different immune system pathways:

• IL-17 inhibitors like secukinumab (Cosentyx) and ixekizumab (Taltz)
• TNF inhibitors such as adalimumab (Humira) and etanercept (Enbrel)
• IL-12/23 inhibitors like ustekinumab (Stelara)

Your doctor will help you choose the best option based on your specific situation, medical history, and how you've responded to previous treatments. Each medication has its own dosing schedule, side effect profile, and considerations.

Is Tildrakizumab Better Than Adalimumab?

Both tildrakizumab and adalimumab are effective treatments for psoriasis, but they work through different mechanisms and have different advantages. The "better" choice depends on your individual needs and medical situation.

Tildrakizumab targets IL-23, while adalimumab blocks TNF-alpha. Clinical studies suggest that tildrakizumab may be more effective for achieving clear or almost clear skin in some people, particularly those with moderate to severe psoriasis.

The dosing schedules differ significantly between these medications. Tildrakizumab is given every 12 weeks after the initial doses, while adalimumab typically requires injections every other week. This less frequent dosing with tildrakizumab might be more convenient for some people.

Side effect profiles also vary between the two medications. Adalimumab has been available longer and has more extensive real-world data, while tildrakizumab is newer with potentially fewer drug interactions and effects on the broader immune system.